SIRPA and hematologic disorder: In agreement with this, TTI-621, a SIRPα-Fc fusion protein that uses the endogenous SIRPα domain to block the CD47-SIRPα axis, was developed by Trillium Therapeutics and is currently being evaluated in phase I trials for hematologic malignancies (NCT02890368).